Abstract

In recent years, the emergence of cancer drug resistance has been one of the crucial tumor hallmarks that are supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters, and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often result in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores the use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

MeSH

Pharmaceutical Preparations, Neoplasms, Drug Resistance, Neoplasm

Cited by

• Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs. Invest Ophthalmol Vis Sci, 2024
• Unveiling the Mechanism of Action of Palmitic Acid, a Human Topoisomerase 1B Inhibitor from the Antarctic Sponge . Int J Mol Sci, 2025
• Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers. Cancers (Basel), 2025
• Cirsiliol suppresses the proliferation of human oral cancer cells by targeting topoisomerase I. 3 Biotech, 2025
• MiCK: a database of gut microbial genes linked with chemoresistance in cancer patients. Database (Oxford), 2024
• Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf. Pharmaceuticals (Basel), 2025
• The multifaceted roles of mucins family in lung cancer: from prognostic biomarkers to promising targets. Front Immunol, 2025
• Redox-Sensitive Camptothecin Prodrug: A Promising Drug Delivery Strategy with Ultrahigh Drug Loading and Tunable Drug Release. Nano TransMed, 2025
• Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol, 2025
• Synthesis and DNA binding studies of novel triazine-isatin hybrids: experimental and computational insights. RSC Adv, 2025